Meta AnalysisID 2062
铜稳态失调与阿尔茨海默病和帕金森病之间关系的新进展：2011年至2020年发表文献的系统评价
CRD42021268819
Are copper dyshomeostasis related to Alzheimer's and Parkinson's diseases? Are copper levels in biofluids (blood, urine, cerebrospinal fluid) and post-mortem tissues altered in patients with Alzheimer's and Parkinson's d
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2062
- Evidence Id
- 10620
- Core Evidence Id
- 10620
- Source Meta Analysis Id
- 2003
- Herb2 Meta Analysis Id
- HBMA002003
- Crd Id
- CRD42021268819
- Title
- What is new about the relationship between copper dyshomeostasis and Alzheimer’s and Parkinson’s disease? A systematic review of manuscripts published between 2011 and 2020.
- Review Question
- Are copper dyshomeostasis related to Alzheimer's and Parkinson's diseases? Are copper levels in biofluids (blood, urine, cerebrospinal fluid) and post-mortem tissues altered in patients with Alzheimer's and Parkinson's disease? Could biofluids or post-mortem tissues be considered for diagnostic purposes for Alzheimer's and Parkinson's diseases? Could altered metal concentrations be related to the severity of Alzheimer's and Parkinson's diseases? What are the effects of increased copper levels that were evidenced in experimental models of Alzheimer's and Parkinson's diseases?
- Study Type Included
- Inclusion: Human: There are no restrictions on the types of study design eligible for inclusion. Animal model: There are no restrictions on the types of study design eligible for inclusion. Exclusion: Human: None. Animal model: None.
- Condition Being Studied
- Relationship between copper and Parkinson's or copper and Alzheimer's Disease
- Participant
- Inclusion: Human: Patients with Azheimer's or Parkinson's disease Animal model: Studies with rats, mice or rabbits. Exclusion: Human: Patients with other neurodegenerative diseases, patients with other metabolic disorders of copper Animal model: Animals other than mice, rats or rabbits, Studies using species that are not an animal model (as plants), in vitro, ex vivo and in silico studies.
- Animal
- Human Disease Modelled
- Intervention
- Inclusion: Human: Studies evaluating copper levels in patients diagnosticated with Alzheimer’s or Parkinson’s disease. Animal model: 1) Studies evaluating the effects of copper exposure; 2) Studies evaluating copper levels in animal models of Alzheimer’s and Parkinson’s disease. All timings, frequencies and dosages of treatments are eligible for inclusion. Exclusion: Human: Patients with other neurodegenerative diseases; patients with other metabolic disorders of copper; people exposed to copper by diet or by occupational exposure. Animal model: Studies evaluating the effects of copper chelators; studies evaluating the effects of a diet deficient in copper; studies evaluating the effects of copper nanoparticles.
- Comparator Control
- Inclusion: Human: Control group: elderly undiagnosed with neurodegenerative diseases (healthy controls); Animal model: 1) Control group (animals not exposed to copper); 2) Animals considered controls of the experimental models of Alzheimer’s or Parkinson’s diseases. Exclusion: Human: Other groups that were not considered the control group. Animal model: Other groups that were not considered the control group.
- Main Outcome
- Inclusion: Human: Association between alterations in copper homeostasis with Parkinson's and Alzheimer's diseases. Animal model: 1) Effects of a copper increase in rats, mice and rabbits and the relationship with Parkinson's and Alzheimer's diseases; 2) Association between alterations in copper homeostasis in Parkinson's and Alzheimer's diseases experimental models (rats, mice or rabbits). Measures of effect Human: Parkinson's and Alzheimer's diseases were diagnosed in clinical laboratories by specialized neurosurgeons following protocols; Measurements of copper levels in biofluids and in post-mortem brain tissues follow different techniques to measure the metal, in order to verify whether copper levels in patients may be related to the onset and progression of Alzheimer's and Parkinson's disease. Animal model: 1) Rats, mice and rabbits exposed to high concentrations of copper; 2) Measurements of copper levels in biofluids and in post-mortem brain tissues follow different techniques to measure the metal in experimental models (rats, mice or rabbits) that mimic Alzheimer's and Parkinson's diseases, in order to verify whether copper levels may be altered
- Outcome Measure
- Additional Outcome
- not applicable Measures of effect not applicable
- Study Method
- Narrative synthesis, Synthesis of qualitative studies, Systematic review
- Keyword
- Alzheimer Disease; Copper; Humans; Parkinson Disease
- Contact
- Fabielly Grotto [email protected]
- Organisational Affiliation
- Universidade Federal de Santa Catarina www.ufsc.br
- Funding Source
- Universidade Federal de Santa Catarina
- Other Selection Criteria
- Final Publication
- Same Topic Review
- not applicate
- Published Protocol
- Review Type
- Language
- English
- Country
- Brazil
- Review Stage
- Review Completed not published
- First Submission Date
- 2021-08-02
- Registration Date
- 2021-09-02
- Anticipated Start Date
- 2021-07-05
- Anticipated Completion Date
- 2022-08-05
- Title Cn
- 铜稳态失调与阿尔茨海默病和帕金森病之间关系的新进展：2011年至2020年发表文献的系统评价
- Title En
- What is new about the relationship between copper dyshomeostasis and Alzheimer’s and Parkinson’s disease? A systematic review of manuscripts published between 2011 and 2020.
- Bilingual Status
- complete